Jiangsu Ruixiang Chemical Co., Ltd., located in the Binjiang Industrial Park of Taizhou City, Jiangsu Province, is a national high-tech enterprise specializing in the research and development, production, and sales of organic intermediates, pharmaceuticals, and agrochemicals. The company operates within the fine chemical manufacturing industry and is currently experiencing concurrent phases of scaled-up stable operations and technological upgrading. Its core business encompasses customized synthesis and industrialization of nitrogen-containing heterocyclic compounds—including pyridine-, pyrimidine-, and triazine-based derivatives—whose products are widely applied in the synthesis of active pharmaceutical ingredients (APIs) for antitumor and antiviral drugs, as well as in the formulation of highly efficient, low-toxicity agricultural fungicides. Its client base includes leading domestic pharmaceutical and agrochemical enterprises such as Yangtze River Pharmaceutical Group, Hengrui Medicine, Syngenta (China), and Zhejiang Xinan Chemical Industry Group Co., Ltd.  

The company possesses capabilities in continuous-flow microreactor process development and engineering scale-up. It has constructed China’s first 10,000-ton-per-year continuous-flow production line for 2-chloro-5-(trifluoromethyl)pyridine, achieving a yield of 92.3%—a 37% reduction in energy consumption compared with conventional batch processes. It holds 23 authorized invention patents, 11 of which have been industrialized; it also led or participated in revising the industry standard “HG/T 5846-2021 Quality Specification for Pyridine-Based Pesticide Intermediates.”  

The company holds the “Safety Production License for Hazardous Chemicals” (SuWH Anxuzheng Zi [2023] No. 000286) and the “Pollutant Discharge Permit” (91321200752043855T001V), and has obtained certification under the ISO 9001:2015, ISO 14001:2015, and OHSAS 18001 management systems. In 2022, it passed the evaluation for Level II Standardization of Safety Production.  

Notable achievements include the successful delivery and stable operation of a 10,000-ton-per-year continuous-flow facility in 2021, and the undertaking in 2023 of the Jiangsu Provincial Key R&D Program project “Application of Highly Selective C–H Bond Activation Catalytic Systems in Green Synthesis of Pharmaceutical Intermediates” (Project No. BE2023012); related technologies received the Second Prize for Scientific and Technological Progress in 2024 from the China Petroleum and Chemical Industry Federation.  

Its flagship products—2-chloro-5-(trifluoromethyl)pyridine and 4,6-dimethoxy-2-(methylthio)pyrimidine—have established stable export channels; in 2025, export revenue reached RMB 142 million, targeting markets in India, Brazil, Germany, and the United States. Supplies to Indian Dr. Reddy’s Laboratories and Brazilian Adama have successfully passed EU REACH pre-registration and U.S. EPA compliance reviews. Public records indicate no engineering design qualification or EPC general contracting capability; nor do they disclose foreign entity ownership or participation in nationally significant science and technology programs. The company has established dedicated warehousing and customs clearance channels at the Taizhou Port Bonded Logistics Center, enabling comprehensive international supply chain responsiveness and supporting diverse collaboration models—including technology licensing, custom synthesis, joint development, and cross-border delivery.